Loading insider details...
Beta
Latest Form 4 (Jul 17, 2026): Sale of 9,500 GLUE shares, $220.2K.
Every alert includes an AI-written analysis of the filing, plus news and market context.
| Filed | Company | Transaction | Shares | Value |
|---|---|---|---|---|
| Jul 17, 2026 | Monte Rosa Therapeutics, Inc. (GLUE) | Sale | 9,500 | $220.2K |
| Jun 2, 2026 | Monte Rosa Therapeutics, Inc. (GLUE) | Sale | 4,998 | $97.0K |
| May 5, 2026 | Monte Rosa Therapeutics, Inc. (GLUE) | Sale | 5,467 | $103.4K |
| Apr 15, 2026 | Monte Rosa Therapeutics, Inc. (GLUE) | Sale | 8,000 | $141.1K |
| Mar 4, 2026 | Monte Rosa Therapeutics, Inc. (GLUE) | Sale | 5,466 | $98.0K |
| Jan 9, 2026 | Monte Rosa Therapeutics, Inc. (GLUE) | Sale | 3,707 | $86.2K |
| Jan 5, 2026 | Monte Rosa Therapeutics, Inc. (GLUE) | Grant/Award | 90,000 | n/a |
| Jan 6, 2025 | Monte Rosa Therapeutics, Inc. (GLUE) | Grant/Award | 128,000 | n/a |
| Jan 4, 2024 | Monte Rosa Therapeutics, Inc. (GLUE) | Grant/Award | 346,000 | n/a |
| Jan 4, 2023 | Monte Rosa Therapeutics, Inc. (GLUE) | Grant/Award | 472,000 | n/a |